Can-Fite BioPharma Ltd.

Industry

  • Biotechnology
    • Drug Discovery Technologies
  • Pharmaceuticals
    • Vaccines

Other Names/Subsidiaries

  • EyeFite
  • Can-Fite technologies
See more in Biomedtracker

Latest on Can-Fite BioPharma Ltd.

Scrip

Can Can-Fite’s Piclidenoson Put Up A Fight In Psoriasis?

 
• By Alaric DeArment

Top-line results from Can-Fite BioPharma Ltd. ’s Phase III COMFORT trial of piclidenoson showing superiority over placebo in psoriasis may warrant moving the drug forward in a registrational trial. B

Scrip

Tech Transfer Roundup: Coronavirus Research Collaborations Respond To Pandemic

 
• By Joseph Haas

Ridgeback To Lead Development Of Emory University Viral Replication Inhibitor Privately held Ridgeback Biotherapeutics LP and Emory University y announced on 19 March they will work together to advan

Scrip

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

 
• By Joseph Haas, John Davis, Alex Shimmings, Jung Won Shin, and Ian Haydock

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Jounce Gets $50m Up Front As

Scrip

Can-Fite Plans Phase III For Namodenoson, Despite Liver Cancer Trial Failure

 
• By Emily Hayes

Israeli company Can-Fite BioPharma Ltd. says that it is moving the A3 adenosine receptor antagonist namodenoson (CF102) forward into pivotal testing, despite the failure of the drug in a Phase II tr